Kathleen D. Rigaut, Ph.D.

krigaut@ddhs.com

Dr. Rigaut received a B.A. in Biology from Virginia Wesleyan College in 1982, a M.S. in Microbiology from N.Y. Medical College in 1985 and a Ph.D. in Microbiology and Molecular Genetics from Rutgers University in 1992. Dr. Rigaut was admitted to practice before the USPTO in 1998 and received a J.D. degree from Rutgers University in Camden in 1999. Dr. Rigaut was admitted to practice law in NJ and PA in 2000 and became a shareholder of the firm in 2002.

Dr. Rigaut has extensive laboratory experience in the fields of virology, immunology and molecular biology. As a Staff Fellow at the National Institutes of Health, Dr. Rigaut was involved in the development of novel immunotoxins targeting the T Cell Receptor.

Publications co-authored by Dr. Rigaut include “Anti-CD3/CD4-CRM9: A Novel Bifunctional Immunotoxin Targeting CD3+CD4+ T Cells,” Tumor Targeting 2:76-84; “Selective Killing of T Cells by Immunotoxins Directed at Distinct Regions of the T Cell Receptor,” Eur. J. Immunol. 25:2077-2082; “Inhibition of VSV Infection by Staurosporine,” Virology 194:433-440; “Intracellular Distribution of Input Vesicular Stomatitis Virus Proteins after Uncoating,” J. Virology 65:2622-2628. Dr. Rigaut contributed a chapter on the clinical use of monoclonal antibodies for a book entitled “Biopharmaceutical Drug Design and Development” published by Humana Press in 1999. Dr. Rigaut has also contributed a book chapter to Research administration and Management Elliott C. Kulakowski, Lynne U. Chronister eds, Research Enterprise entitled “Applying for United States Patent Protection” Dr. Rigaut has written a chapter on non-disclosure agreements which also appeared in Research Administration and Management.

Dr. Rigaut has extensive experience in patent prosecution, including preparation and filing of patent applications, amendments and responses to PTO Official Actions on a variety of subjects including cancer genes, transgenic plants, RNA viruses, monoclonal antibodies, antisense technologies and compositions involved in anti-inflammatory responses. She also prepared patentability and freedom to operate opinions.

Dr. Rigaut is a member of the Philadelphia Intellectual Property Law Association (PIPLA), the Association of University Technology Managers (AUTM) and the Licensing Executive Society (LES).